SARS-CoV-2 - Colchicine - Therapeutic Candidates

SARS-CoV-2 - Colchicine - Therapeutic Candidates


Colchicine is an anti-inflammatory drug used in rheumatology and particularly for the treatment of gouty arthritis or gout. Colchicine is also used in the treatment of other pathologies such as chronic atrophic polychondritis or acute pericarditis after failure of aspirin. 
Studies have shown that SARS-CoVs activate NLRP3 inflammasomes, intracytoplasmic particles that stimulate the release of pro-inflammatory cytokines. In particular, colchicine is believed to inhibit the assembly of the NLRP3 inflammasome and thus the release of cytokines, in particular interleukin-1 beta and interleukin-6. Colchicine is believed to inhibit certain functions of the inflammasome, a component of the immune system that plays a role in triggering cytokine shock and the associated inflammatory cascade. Targeting the inflammatory response with colchicine may therefore reduce complications related to Covid-19 in adults at risk or with signs of inflammatory storm. Three studies are currently underway to investigate the effects of colchicine on Covid-19, the largest, called COLCORONA, involves 6000 patients in Canada.

Cat#
Description
Size
Price Excl. VAT
HY-16569-S
 0,5-1mg 
JM-1519-1000
 1g 
HY-16569-1mL
 10mM/1mL 
HY-16569-200mg
 200mg 
HY-16569-500mg
 500mg 
271420-100mg
 100mg 
40300104-1
 1g 
271420-25mg
 25mg 
40300104-2
 5g 
271420-50mg
 50mg 
271421-100mg
 100mg 
271421-25mg
 25mg 
271421-50mg
 50mg 
268672-100mg
 100mg 
T-2789-25mg
 25mg 
268672-25mg
 25mg 
T-2789-5mg
 5mg 
268672-50mg
 50mg 
271420-10mg
 10mg 
271420-5mg
 5mg 
271421-10mg
 10mg 
271421-5mg
 5mg 
Number of results per page : 10 50 250